London neurotech startup Lyeons Limited raises £129k

Neurotechnology startup Lyeons Limited has secured an estimated £129k in a new funding round. The London-based company, which was incorporated in 2024, develops stimulation-based solutions designed to support brain health. Its core product is LYEONS Heart, a portable device that utilizes sensory modulation technology to recalibrate the autonomic nervous system. This hardware is intended to provide support for individuals experiencing physical anxiety, stress, trauma, and sleep disturbances.

This latest investment brings the company to an estimated post-money valuation of £2.9m. Financial records for the year ended 31 October 2025 indicate that the business operated with two employees at that time. Documentation for the share allotment was filed in September 2026.